Dirk M. van der Steen

1.0k citations

28 papers · 747 indexed · h-index 14

Co-authors: Mirjam H.M. Heemskerk Renate S. Hagedoorn J.H. Frederik Falkenburg Peter A. van Veelen Arnoud H. de Ru Michel G.D. Kester Marieke Griffioen Inge Jedema
Topics: CAR-T cell therapy research (18 papers)Immunotherapy and Immune Responses (15 papers)Immune Cell Function and Interaction (9 papers)
Cited by: Immunology Oncology Hematology
Journals: Journal of Clinical Investigation Blood The Journal of Immunology
Partner nations: Netherlands United States United Kingdom

In The Last Decade

Dirk M. van der Steen

28 papers receiving 733 citations

Peers

Countries citing papers authored by Dirk M. van der Steen

Since Specialization

Citations

This map shows the geographic impact of Dirk M. van der Steen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Dirk M. van der Steen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Dirk M. van der Steen more than expected).

Fields of papers citing papers by Dirk M. van der Steen

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Dirk M. van der Steen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Dirk M. van der Steen. The network helps show where Dirk M. van der Steen may publish in the future.

Co-authorship network of co-authors of Dirk M. van der Steen

This figure shows the co-authorship network connecting the top 25 collaborators of Dirk M. van der Steen. A scholar is included among the top collaborators of Dirk M. van der Steen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Dirk M. van der Steen. Dirk M. van der Steen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	PRAME and CTCFL-reactive TCRs for the treatment of ovarian cancer 2023 ·Frontiers in Immunology ·(unknown),(unknown),Anne K. Wouters,Marian van de Meent,(unknown),(unknown),(unknown),Dennis F.G. Remst,Renate S. Hagedoorn,Dirk M. van der Steen,Arnoud H. de Ru,Els M.E. Verdegaal,Peter A. van Veelen,J.H. Frederik Falkenburg,Mirjam H.M. Heemskerk	16
2	Broadly applicable TCR-based therapy for multiple myeloma targeting the immunoglobulin J chain 2023 ·Journal of Hematology & Oncology ·(unknown),Anne K. Wouters,(unknown),Renate S. Hagedoorn,Michel G.D. Kester,Dennis F.G. Remst,Dirk M. van der Steen,Arnoud H. de Ru,(unknown),(unknown),Marieke Griffioen,Peter A. van Veelen,J.H. Frederik Falkenburg,Mirjam H.M. Heemskerk	9
3	Cutting Edge: Unconventional CD8+ T Cell Recognition of a Naturally Occurring HLA-A02:01–Restricted 20mer Epitope 2022 ·The Journal of Immunology* ·(unknown),Anne K. Wouters,Renate S. Hagedoorn,Michel G.D. Kester,Dennis F.G. Remst,Dirk M. van der Steen,Arnoud de Ru,Peter A. van Veelen,Jamie Rossjohn,Stéphanie Gras,J.H. Frederik Falkenburg,Mirjam H.M. Heemskerk	3
4	A library of cancer testis specific T cell receptors for T cell receptor gene therapy 2022 ·Molecular Therapy — Oncolytics ·(unknown),Dennis F.G. Remst,Dirk M. van der Steen,Anne K. Wouters,Renate S. Hagedoorn,Michel G.D. Kester,(unknown),(unknown),Arnoud H. de Ru,Peter A. van Veelen,Els M.E. Verdegaal,J.H. Frederik Falkenburg,Mirjam H.M. Heemskerk	11
5	WT1-specific TCRs directed against newly identified peptides install antitumor reactivity against acute myeloid leukemia and ovarian carcinoma 2022 ·Journal for ImmunoTherapy of Cancer ·(unknown),Renate S. Hagedoorn,Dennis F.G. Remst,(unknown),Dirk M. van der Steen,Anne K. Wouters,Marian van de Meent,Michel G.D. Kester,Arnoud H. de Ru,Marieke Griffioen,Peter A. van Veelen,J.H. Frederik Falkenburg,Mirjam H.M. Heemskerk	17
6	A broad and systematic approach to identify B cell malignancy-targeting TCRs for multi-antigen-based T cell therapy 2021 ·Molecular Therapy ·(unknown),Anne K. Wouters,Lorenz Jahn,Renate S. Hagedoorn,Michel G.D. Kester,Dennis F.G. Remst,Laura T. Morton,Dirk M. van der Steen,(unknown),Arnoud H. de Ru,Marieke Griffioen,Peter A. van Veelen,J.H. Frederik Falkenburg,Mirjam H.M. Heemskerk	9
7	Healthy cells functionally present TAP-independent SSR1 peptides: implications for selection of clinically relevant antigens 2021 ·iScience ·(unknown),(unknown),(unknown),Dirk M. van der Steen,Marlieke L.M. Jongsma,(unknown),(unknown),Arnoud H. de Ru,Arie Admon,Peter A. van Veelen,Marieke Griffioen,Mirjam H.M. Heemskerk,Robbert M. Spaapen	3
8	Mutated nucleophosmin 1 as immunotherapy target in acute myeloid leukemia 2019 ·Journal of Clinical Investigation ·(unknown),Rogier M. Reijmers,(unknown),Renate S. Hagedoorn,Rob C. M. de Jong,Michel G.D. Kester,Dirk M. van der Steen,Arnoud H. de Ru,(unknown),(unknown),Inge Jedema,Hendrik Veelken,Peter A. van Veelen,Mirjam H.M. Heemskerk,J.H. Frederik Falkenburg,Marieke Griffioen	127
9	Preclinical Strategies to Identify Off-Target Toxicity of High-Affinity TCRs 2018 ·Molecular Therapy ·(unknown),Dirk M. van der Steen,Renate S. Hagedoorn,Anne K. Wouters,Linda Wooldridge,J.H. Frederik Falkenburg,Mirjam H.M. Heemskerk	37
10	Mutated NPM1 As Target for Immunotherapy of Acute Myeloid Leukemia 2017 ·Blood ·(unknown),(unknown),Renate S. Hagedoorn,(unknown),Michel G.D. Kester,Dirk M. van der Steen,Arnoud H. de Ru,Inge Jedema,Hendrik Veelken,Mirjam H.M. Heemskerk,Peter A. van Veelen,J.H. Frederik Falkenburg,Marieke Griffioen	1
11	PRAME as a Potential Target for Immunotherapy in Metastatic Uveal Melanoma 2017 ·JAMA Ophthalmology ·Gülçin Gezgin,(unknown),Jinfeng Cao,Mehmet Doğrusöz,Dirk M. van der Steen,Renate S. Hagedoorn,Daniëlle Krijgsman,Pieter A. van der Velden,Matthew G. Field,Gregorius P. M. Luyten,Károly Szuhai,J. William Harbour,Ekaterina S. Jordanova,Mirjam H.M. Heemskerk,Martine J. Jager	86
12	T Cell Receptor Gene Therapy Targeting the Intracellular Transcription Factor Bob1 for the Treatment of Multiple Myeloma and Other B Cell Malignancies 2015 ·Blood ·Lorenz Jahn,Renate S. Hagedoorn,Pleun Hombrink,Michel G.D. Kester,Dirk M. van der Steen,Cesare Hassan,(unknown),(unknown),Peter A. van Veelen,J.H. Frederik Falkenburg,Mirjam H.M. Heemskerk	1
13	Natural killer cells facilitate PRAME-specific T-cell reactivity against neuroblastoma 2015 ·Oncotarget ·Lotte Spel,Jaap Jan Boelens,Dirk M. van der Steen,(unknown),Max M. van Noesel,Jan J. Molenaar,Mirjam H.M. Heemskerk,Marianne Boes,Stefan Nierkens	39
14	T Cell Receptors Specific for the Intracellular Transcription Factor Bob1 Allow Efficient Targeting of Human B Cell Leukemia and Multiple Myeloma 2014 ·Blood ·Lorenz Jahn,Pleun Hombrink,Michel G.D. Kester,Dirk M. van der Steen,Renate S. Hagedoorn,Cesare Hassan,(unknown),(unknown),Peter A. van Veelen,J.H. Frederik Falkenburg,Mirjam H.M. Heemskerk	1
15	HLA Monomers as a Tool to Monitor Indirect Allorecognition 2014 ·Transplantation ·Eytan Breman,(unknown),Dirk M. van der Steen,Mirjam H.M. Heemskerk,Ilias I.N. Doxiadis,Dave L. Roelen,Frans H.J. Claas,Cees van Kooten	10
16	PRAME-Specific Allo-HLA–Restricted T Cells with Potent Antitumor Reactivity Useful for Therapeutic T-Cell Receptor Gene Transfer 2011 ·Clinical Cancer Research ·Avital L. Amir,Dirk M. van der Steen,Marleen M. van Loenen,Renate S. Hagedoorn,Renate de Boer,(unknown),Arnoud H. de Ru,Gertjan Lugthart,Cees van Kooten,Pieter S. Hiemstra,Inge Jedema,Marieke Griffioen,Peter A. van Veelen,J.H. Frederik Falkenburg,Mirjam H.M. Heemskerk	92
17	Combined CD8+ and CD4+ adenovirus hexon-specific T cells associated with viral clearance after stem cell transplantation as treatment for adenovirus infection 2010 ·Haematologica ·Maarten L. Zandvliet,J.H. Frederik Falkenburg,Ellis van Liempt,Louise A. Veltrop‐Duits,Arjan C. Lankester,Jayant Kalpoe,(unknown),Dirk M. van der Steen,Maarten J. van Tol,Roel Willemze,Henk‐Jan Guchelaar,Marco W. Schilham,Pauline Meij	54
18	Combined CD8+ and CD4+ adenovirus hexon-specific T cells associated with viral clearance after stem cell transplantation as treatment for adenovirus infection Running head: M. Zandvliet et al. HAdV-specific T cells after alloSCT 2010 ·Maarten L. Zandvliet,Ellis van Liempt,Louise A. Veltrop‐Duits,Arjan C. Lankester,Jayant Kalpoe,Dirk M. van der Steen,Maarten J. van Tol,Roel Willemze,Henk‐Jan Guchelaar,Marco W. Schilham,Pauline Meij	2
19	Identification of Varicella-Zoster Virus-Specific CD8 T Cells in Patients after T-Cell-Depleted Allogeneic Stem Cell Transplantation 2009 ·Journal of Virology ·Pim L. J. van der Heiden,Renate de Boer,Dirk M. van der Steen,Michel G.D. Kester,(unknown),(unknown),(unknown),Jeremy Fry,(unknown),Erik W.A. Marijt,Roel Willemze,J.H. Frederik Falkenburg,Mirjam H.M. Heemskerk	13
20	Stable Recombinase-Mediated Cassette Exchange in Arabidopsis UsingAgrobacterium tumefaciens 2007 ·PLANT PHYSIOLOGY ·Jeanine Louwerse,(unknown),Dirk M. van der Steen,(unknown),Paul J. J. Hooykaas,Annette C. Vergunst	44

About Dirk M. van der Steen

Dirk M. van der Steen is a scholar working on Immunology, Oncology and Radiology, Nuclear Medicine and Imaging, having authored 28 papers that have together received 747 indexed citations. Recurring topics across this work include CAR-T cell therapy research (18 papers), Immunotherapy and Immune Responses (15 papers) and Immune Cell Function and Interaction (9 papers). The work is most often cited by research in Immunology (432 citations), Oncology (440 citations) and Hematology (109 citations). Dirk M. van der Steen has collaborated with scholars based in Netherlands, United States and United Kingdom. Frequent co-authors include Mirjam H.M. Heemskerk, Renate S. Hagedoorn, J.H. Frederik Falkenburg, Peter A. van Veelen, Arnoud H. de Ru, Michel G.D. Kester, Marieke Griffioen, Inge Jedema, Avital L. Amir and Anne K. Wouters. Their work appears in journals such as Journal of Clinical Investigation, Blood and The Journal of Immunology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact